Authors
Latest:
Biosimilars: why deep discounts may become the dominant paradigmEuropean experience to date indicates a changing perspective on biosimilar pricing
Latest:
The Patient-Level Approach to Studying HealthcareLongitudinal patient-level data answer pressing questions about patient safety, outcomes and medication acceptance
Latest:
‘Cliff’ Countdown: Balancing Internal and External GrowthIn this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, explores the two major strategies big pharma companies are employing amid current macro challenges and efforts to offset looming patent losses to blockbuster brands.
Latest:
On-Demand Digital Printing Rewires Pharma PackagingDigital systems are changing the economics and functionality of scheduling and production of printed packaging
Latest:
After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit DrugsIndustry and FDA can—and must—do more to protect global pharmaceutical supply chains
Latest:
Understanding Class of Trade Concepts‘Class of Trade’ is a murky element of contracts and channel analytics that can have important legal implications
Latest:
Fortifying Vaccine Supply ChainsHow they embrace collaboration will be key to the battle against RSV.
Latest:
Reshaping Biotechnology's Financing Relay RaceThe current economic downturn may fuel the creation of new, more sustainable business models
Latest:
Make Adverse Events and Customer Complaints Part of a Holistic Quality Management SystemUsually associated with manufacturing or laboratory processes, quality systems can improve post-marketing compliance efforts
Latest:
Focusing pharma marketing on 'headroom'In the race to improve product performance, not enough attention is paid to 'who's actually going to switch?'
Latest:
A Process-Based Approach To Aggregate SpendA Process-Based Assessment (PBA) is the first step to analyzing reporting needs
Latest:
A growing preference for ready-to-administer vaccines: new guidelines, evidence, and trendsVaccine administration is shifting from multidose vials to prefilled syringes for a host of important safety and economic considerations
Latest:
Regulatory Focus on Off-Label Promotion Is RisingWhile FDA guidance on appropriate medical communication has evolved, US Dept. of Justice attention the practice is intensifying
Latest:
Effective and proactive oversight of master dataGo-to safeguards for manufacturers in avoiding mismanagement of their business-central records
Latest:
Big Pharma requires big help in protecting CRT productsAn inside look at selection and implementation of passive thermal protection
Latest:
With coupons, pharma is saying 'Let's make a deal' to consumersPharma marketers become adept at refining coupon and voucher programs, while technology options multiply. Meanwhile payer criticism mounts
Latest:
NCPDP Standards for Accurate Billing, Reimbursement and AccessThe National Council for Prescription Drug Programs’ (NCPDP) Billing Unit Standard (BUS) brings order to pharmaceutical transactions. Between it, the National Drug Code (NDC) and the Structured Product Label (SPL), all necessary commercial information about a product is known.
Latest:
Preparing the Market for a New Drug with an Effective 'Medical Affairs Launch'The Medical Affairs function can play a vital role in today’s product launch process
Latest:
How tackling counterfeit drugs will drive improvements in the pharma supply chainBig Data and AI will bring value beyond compliance
Latest:
The Rise of 'Companion' Diagnostics for Specialty PharmaceuticalsUnder the theme of personalized medicine, in vitro diagnostics will play an increasingly important role in new drug entries and new therapies
Latest:
Precision medicine and the importance of dataPatient-support Hub services are a vital repository of the patient journey
Latest:
Data security for PharmaCloud computing opens a new array of benefits--and challenges--to data-sharing
Latest:
Ensuring the quality of comparative effectiveness researchAs payers seek higher-quality data from real-world treatment settings, the importance of reliable measures becomes critical
Latest:
Economic Considerations For REMSDrug sponsors have options in both how the new FDA risk programs are structured and how to execute them
Latest:
Recent US Supreme Court decisions narrow life-sciences patentability claimsIndustry response may be to keep more innovations as trade secrets
Latest:
Prilenia Announces Plans to Initiate Global Phase III Study of Novel ALS TreatmentData from prior Phase II study showed signs of pridopidine slowing disease progression in patients with amyotrophic lateral sclerosis.
